Endothelial function changes in paroxysmal atrial fibrillation and treatment with propafenone
https://doi.org/10.15829/1728-8800-2018-4-40-45
Abstract
Aim. To evaluate the changes of endothelial function in arterial hypertension (AH) patients with paroxysmal atrial fibrillation (AF) in treatment with propafenone (Propanorm, PRO.MED.CS Praha a. s.) in comparison with bisoprolol.
Material and methods. To the study, 62 AH patients included with paroxysmal AH, age 45-63 y. o. (mean age 54,5±3,7 y. o.). Patients were randomized to 2 groups: 32 of group 1 (main) for rhythm-control were taking propafenone (Propanorm, PRO.MED.CS Praha a. s.) 450 mg daily, and 30 of group 2 (comparison) were taking bisoprolol for rate control. The groups were comparable by gender, age, severity of AH and duration of arrhythmia. Changes in endothelium vascular motion function and biochemical markers of endothelial dysfunction were assessed at inclusion and in 12 months of therapy.
Results. Sinus rhythm retention in propafenone group facilitated the improvement of vascular motion function of endothelium — endothelium dependent vasodilatation of brachial artery showed tendency to rise significantly from 5,4±0,3% to 6,9±0,1% (р=0,01). In patients taking bisoprolol for pulse reduction during 12 months, there was negative tendency from 4,8±0,2% to 3,6±0,1% (р=0,003), that points on worsening of endothelial function with persistent AF. Repeat measurement of biochemical markers of endothelial dysfunction revealed that in 12 months there is raise of endothelin concentration in both groups. Value of the collagen-binding activeness of von Willebrand factor in 12 months significantly reduced from 131±12 to 118±6 U/dL (р<0,05) in those retaining sinus rhythm with propafenone, and increased from 135±11 U/dL to 147±12 U/dL in those with rate control by bisoprolol.
Conclusion. In AH patients with paroxysmal AF retention of sinus rhythm with propafenone facilitated the improvement of vascular motion function of endothelium and decrease of collagen binding activeness of von Willebrand factor.
About the Authors
V. I. PodzolkovRussian Federation
Moscow
A. I. Tarzimanova
Russian Federation
Moscow
References
1. Anderson JL, Halperin JL, Albert NM, et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC. 2013;61(18):1935-44. doi:10.1016/j.jacc.2013.02.001.
2. Kaireviciuted D, Lip G, Balakrishnan B, et al. Intracardiac expression of markers of endothelial damage / dysfunction, inflammation, thrombosis, and tissue remodeling, and the development of postoperative atrial fibrillation. J Thromb Haemost. 2011;9:2345–52. doi:10.1111/j.1538-7836.2011.04523.x.
3. Deanfield J, Halcox J, Rabelink T. Endothelial function and dysfunction. Circulation. 2007;115:85-95. doi:10.1161/CIRCULATIONAHA.106.652859.
4. Komej J, Apostolakis S, Bollmann A, et al. The emerging role of biomarkers in atrial fibrillation. Can J Cardiol. 2013;29(10):1181-93. doi:10.1016/j.cjca.2013.04.016.
5. Scridon A, Girerd N, Rugeri L, et al. Progressive endothelial damage revealed by multilevel von Willebrand factor plasma concentration in atrial fibrillation patients. Europace. 2013;15(11):1562-6. doi:10.1093/europace/eut121.
6. Celermajer D. Non-invasive detection of endothelial disfunction in children and adult at risk of atherosclerosis. Lancet. 1992;340:1111-5.
7. Ionescu-Ittu R, Abrahamowicz M, Jack Evicius C, et al. Comparative effectiveness of rhythm control vs rate control drug treatment effect on mortality in patients with atrial fibrillation. Arch Intern Med. 2012;172:997-1004. doi:10.1001/archinternmed.2012.2266.
8. Camm A, Savelieva I. Atrial fibrillation: the rate versus rhythm management controversy. J R Coll Physicians Edinb. 2012;42(18):23-34. doi:10.4997/JRCPE.2012.S03.
9. Yoshino S, Yoshikawa A, Hamasaki S, et al. Atrial fibrillation-induced endothelial dysfunction improves after restoration of sinus rhythm. Int J Cardiol. 2013;168(2):1280-5. doi:10.1016/j.ijcard.2012.12.006.
10. Freestone B, Chong A, Nuttall S, et al. Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res. 2008;122(1):85-90. doi:10.1016/j.thromres.2007.09.008.
11. Ammash N, Konik E, McBane R, et al. Left atrial blood stasis and von Willebrand factor — ADAMTS13 homeostasis in atrial fibrillation. Arterioscler Throm Vasc Biol. 2011;31(11):2760-6. doi:10.1161/ATVBAHA.111.232991.
Review
For citations:
Podzolkov V.I., Tarzimanova A.I. Endothelial function changes in paroxysmal atrial fibrillation and treatment with propafenone. Cardiovascular Therapy and Prevention. 2018;17(4):40-45. (In Russ.) https://doi.org/10.15829/1728-8800-2018-4-40-45